Company attributes
Other attributes
XORTX Therapeutics Inc (XORTX) is a drug development company that primarily focuses on orphan disease indications which have a uric acid imbalance as well as metabolic syndrome, diabetes and diabetic nephropathy.
XORTX possesses patents and patent applications that may include US and international rights regarding the development of uric acid lowering agents for the treatment of Hypertension, Insulin Resistance, Diabetes, Metabolic Syndrome and Kidney Injury.
XORTX is developing oxypurinol, a uric acid lowering agent. Its uric acid lowering agent has an established safety and effectiveness profile which the FDA previously allowed for treating gout on a compassionate basis, when patients could not tolerate Allopurinol.
XORTX Therapeutics has three products in clinical development, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease, XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic Nephropathy (T2DN).
The company has intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development-stage products that target xanthine oxidase to inhibit production of uric acid. The company is dedicated to developing medications to enhance the quality of life and future of patients.
